In addition, these beneficial effects of ACE2 on doxorubicin-induced cardiomyopathy are likely to root in the interactions of shifting RAS components, such as decreased myocardium AngII levels, increased myocardium Ang (1–7) levels, and reduced ACE expression. Here, ACE2 is linked to cardiomyopathy.